The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

MOLINDONE     3-ethyl-2-methyl-5- (morpholin-4-ylmethyl)...

Synonyms: Molindona, Molindonum, Moban, CHEMBL460, PubChem21442, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of MOLINDONE


Psychiatry related information on MOLINDONE


High impact information on MOLINDONE


Chemical compound and disease context of MOLINDONE

  • Haloperidol treatment masked withdrawal-exacerbated tardive dyskinesia more than molindone did; this difference (measured by percent change in AIMS scores) was significant (p = .04) when the dose was 200% but not 100% of the prestudy neuroleptic dose [13].

Biological context of MOLINDONE


Anatomical context of MOLINDONE

  • Treatment of clozapine- and molindone-induced agranulocytosis with granulocyte colony-stimulating factor [18].
  • The effect of molindone on the activity of dopaminergic (DA) neurons in the rat midbrain and on DA metabolism in the striatum and olfactory tubercles was studied using extracellular single unit recording and biochemical techniques respectively [19].

Associations of MOLINDONE with other chemical compounds


Gene context of MOLINDONE


Analytical, diagnostic and therapeutic context of MOLINDONE


  1. Tardive dyskinesia associated with molindone treatment. Katz, S.E. The American journal of psychiatry. (1990) [Pubmed]
  2. Weight reduction in schizophrenics by molindone. Gardos, G., Cole, J.O. The American journal of psychiatry. (1977) [Pubmed]
  3. Galactorrhea associated with molindone. Wesp, C.E., Annitto, W., Feinsod, R. The American journal of psychiatry. (1979) [Pubmed]
  4. A case of massive rhabdomyolysis following molindone administration. Johnson, S.B., Alvarez, W.A., Freinhar, J.P. The Journal of clinical psychiatry. (1986) [Pubmed]
  5. Weight gain associated with antipsychotic drugs. Ganguli, R. The Journal of clinical psychiatry. (1999) [Pubmed]
  6. Enhanced stereotyped response to amphetamine after pretreatment with small doses of molindone. Conway, P., Uretsky, N.J. Neuropharmacology (1983) [Pubmed]
  7. Dopaminergic agents including 3-PPP and its enantiomers on medial septal self-stimulation. Gower, A.J., Broekkamp, C.L. Pharmacol. Biochem. Behav. (1985) [Pubmed]
  8. Molindone and hepatotoxicity. Bhatia, S.C., Banta, L.E., Ehrlich, D.W. Drug intelligence & clinical pharmacy. (1985) [Pubmed]
  9. Molindone hydrochloride: a review of laboratory and clinical findings. Owen, R.R., Cole, J.O. Journal of clinical psychopharmacology. (1989) [Pubmed]
  10. Relation of serum molindone levels to serum prolactin levels and antipsychotic response. Pandurangi, A.K., Narasimhachari, N., Blackard, W.G., Landa, B.S. The Journal of clinical psychiatry. (1989) [Pubmed]
  11. Rhabdomyolysis and molindone. Pandurangi, A.K., Narasimhachari, N. The Journal of clinical psychiatry. (1988) [Pubmed]
  12. Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. Escobar, J.I., Mann, J.J., Keller, J., Wilkins, J., Mason, B., Mills, M.J. The Journal of clinical psychiatry. (1985) [Pubmed]
  13. Molindone and haloperidol in tardive dyskinesia. Glazer, W.M., Hafez, H.M., Benarroche, C.L. The Journal of clinical psychiatry. (1985) [Pubmed]
  14. Review of clinical and laboratory experiences with molindone hydrochloride. Claghorn, J.L. The Journal of clinical psychiatry. (1985) [Pubmed]
  15. A comparison of the abilities of chlorpromazine and molindone to interact adversely with guanethidine. Gilder, D.A., Fain, W., Simpson, L.L. J. Pharmacol. Exp. Ther. (1976) [Pubmed]
  16. Down-regulation of tryptamine binding sites following chronic molindone administration. A comparison with responses of dopamine and 5-hydroxytryptamine receptors. Nguyen, T.V., Juorio, A.V. Naunyn Schmiedebergs Arch. Pharmacol. (1989) [Pubmed]
  17. Tissue distribution of molidone in a multidrug overdose. Flammia, D.D., Bateman, H.R., Saady, J.J., Christensen, E.D. Journal of analytical toxicology. (2004) [Pubmed]
  18. Treatment of clozapine- and molindone-induced agranulocytosis with granulocyte colony-stimulating factor. Geibig, C.B., Marks, L.W. The Annals of pharmacotherapy. (1993) [Pubmed]
  19. Effects of molindone on central dopaminergic neuronal activity and metabolism: similarity to other neuroleptics. Bunney, B.S., Roth, R.H., Aghajanian, G.K. Psychopharmacology communications. (1975) [Pubmed]
  20. A comparative study of parenteral molindone and haloperidol in the acutely psychotic patient. Binder, R., Glick, I., Rice, M. The Journal of clinical psychiatry. (1981) [Pubmed]
  21. Molindone hydrochloride treatment of hospitalized children with conduct disorder. Greenhill, L.L., Solomon, M., Pleak, R., Ambrosini, P. The Journal of clinical psychiatry. (1985) [Pubmed]
  22. Effects of molindone and fluphenazine on the brain concentration of some phenolic and catecholic amines in the mouse and the rat. Juorio, A.V. Br. J. Pharmacol. (1980) [Pubmed]
  23. Differential regulation of D2 and D4 dopamine receptor mRNAs in the primate cerebral cortex vs. neostriatum: effects of chronic treatment with typical and atypical antipsychotic drugs. Lidow, M.S., Goldman-Rakic, P.S. J. Pharmacol. Exp. Ther. (1997) [Pubmed]
  24. Differential dose- and time-dependent effects of molindone on dopamine neurons of rat brain: mediation by irreversible inhibition of monoamine oxidase. Meller, E., Friedman, E. J. Pharmacol. Exp. Ther. (1982) [Pubmed]
  25. Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Andersen, P.H. Eur. J. Pharmacol. (1988) [Pubmed]
  26. Psychopharmacological investigation of the monoamine oxidase inhibitory activity of molindone, a dihydroindolone neuroleptic. Balsara, J.J., Gada, V.P., Nandal, N.V., Chandorkar, A.G. J. Pharm. Pharmacol. (1984) [Pubmed]
  27. Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats. Meller, E. Psychopharmacology (Berl.) (1982) [Pubmed]
  28. Effects of amantadine on modification of dopamine dependent behaviours by molindone. Dhaware, B.S., Balsara, J.J., Nandal, N.V., Chandorkar, A.G. Indian journal of medical sciences. (2000) [Pubmed]
WikiGenes - Universities